XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2.u1
GOODWILL AND INTANGIBLE ASSETS (Changes in Carrying Amount of Goodwill) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Goodwill [Line Items]          
Amortization of intangibles and other assets $ 62.2 $ 51.5 $ 122.3 $ 104.9  
Intangible Assets, Gross (Excluding Goodwill) 5,149.7   5,149.7   $ 5,058.4
Balance as of January 1     6,142.5    
Adjustments to goodwill     (64.0)    
Balance at end of period 6,220.2   6,220.2    
Finite-Lived Intangible Assets, Accumulated Amortization 1,817.7   1,817.7   1,716.4
Intangible Assets, Net (Excluding Goodwill) $ 3,332.0   3,332.0   3,342.0
Goodwill, Acquired During Period     141.7    
Goodwill [Roll Forward]          
Goodwill and Intangible Assets, Goodwill, Policy
6.    GOODWILL AND INTANGIBLE ASSETS
The changes in the carrying amount of goodwill for the six months ended June 30, 2024, were as follows:
DxBLSTotal
Balance as of December 31, 2023$4,813.9 $1,328.6 $6,142.5 
Goodwill acquired during the period141.7 — 141.7 
Foreign currency impact and other adjustments to goodwill(10.7)(53.3)(64.0)
Balance as of June 30, 2024$4,944.9 $1,275.3 $6,220.2 
The Company assesses goodwill and indefinite-lived intangibles for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company recognizes an impairment charge for the amount by which the reporting unit's carrying amount exceeds its fair value.
Although the Company believes that the current assumptions and estimates used in its goodwill analysis are reasonable, supportable, and appropriate, the Company's business could be impacted by unfavorable changes, including those that impact the existing assumptions used in the impairment analysis. Various factors could reasonably be expected to unfavorably impact existing assumptions: primarily, a worsening economic environment and protracted economic downturn and related impacts, including delays in revenue from new customers; increases in customer termination activity; or increases in operating costs. Accordingly, there can be no assurance that the estimates and assumptions made for the purposes of the goodwill impairment analysis will prove to be accurate predictions of future performance.
The Company will continue to monitor the financial performance of, and assumptions for, its reporting units. A significant increase in the discount rate, decrease in the revenue and terminal growth rates, decreased operating margin, or substantial reductions in end markets and volume assumptions, could have a negative impact on the estimated fair value of the reporting units. A future impairment charge for goodwill or intangible assets could have a material effect on the Company's consolidated financial position and results of operations.
The components of identifiable intangible assets were as follows:
 June 30, 2024December 31, 2023
Gross Carrying AmountAccumulated AmortizationNetGross Carrying AmountAccumulated AmortizationNet
Customer relationships$3,947.8 $(1,444.1)$2,503.7 $3,868.6 $(1,367.2)$2,501.4 
Patents, licenses, and technology520.3 (283.1)237.2 526.6 (273.3)253.3 
Non-compete agreements152.4 (72.5)79.9 130.3 (60.4)69.9 
Canadian licenses495.1 — 495.1 498.8 — 498.8 
Other34.1 (18.0)16.1 34.1 (15.5)18.6 
 5,149.7 (1,817.7)3,332.0 5,058.4 (1,716.4)3,342.0 
Amortization of intangible assets for the three and six months ended June 30, 2024, and 2023, was $62.2 and $51.5 and $122.3 and $104.9, respectively. The amortization expense for the net carrying amount of intangible assets is estimated to be $125.0 for the remainder of fiscal 2024, $237.2 in fiscal 2025, $228.2 in fiscal 2026, $216.9 in fiscal 2027, $209.1 in fiscal 2028, and $1,735.8 thereafter.
       
LabCorp Diagnostics [Member]          
Goodwill [Line Items]          
Balance as of January 1     4,813.9    
Adjustments to goodwill     (10.7)    
Balance at end of period $ 4,944.9   4,944.9    
Goodwill, Acquired During Period     141.7    
Covance Drug Development [Member]          
Goodwill [Line Items]          
Balance as of January 1     1,328.6    
Adjustments to goodwill     (53.3)    
Balance at end of period 1,275.3   1,275.3    
Goodwill, Acquired During Period     0.0    
Customer Relationships [Member]          
Goodwill [Line Items]          
Intangible Assets, Gross (Excluding Goodwill) 3,947.8   3,947.8   3,868.6
Finite-Lived Intangible Assets, Accumulated Amortization 1,444.1   1,444.1   1,367.2
Intangible Assets, Net (Excluding Goodwill) 2,503.7   2,503.7   2,501.4
Patents, Licenses And Technology [Member]          
Goodwill [Line Items]          
Intangible Assets, Gross (Excluding Goodwill) 520.3   520.3   526.6
Finite-Lived Intangible Assets, Accumulated Amortization 283.1   283.1   273.3
Intangible Assets, Net (Excluding Goodwill) 237.2   237.2   253.3
Noncompete Agreements [Member]          
Goodwill [Line Items]          
Intangible Assets, Gross (Excluding Goodwill) 152.4   152.4   130.3
Finite-Lived Intangible Assets, Accumulated Amortization 72.5   72.5   60.4
Intangible Assets, Net (Excluding Goodwill) 79.9   79.9   69.9
Canadian licenses [Member]          
Goodwill [Line Items]          
Intangible Assets, Gross (Excluding Goodwill) 495.1   495.1   498.8
Finite-Lived Intangible Assets, Accumulated Amortization 0.0   0.0   0.0
Intangible Assets, Net (Excluding Goodwill) $ 495.1   $ 495.1   $ 498.8